地缘政治方面，伊以停火协议虽然生效，但市场对其维持的信心不足。伊朗对美军基地的打击和以色列对德黑兰的空袭，都显示出局势的不确定性。这 种不确定性可能会对能源和黄金市场产生影响，咱们在投资时要做好风险管理。 中概股方面，纳斯达克中国金龙指数涨3.31%，创5月13日以来最大单日涨幅。小马智行、新东方、金山云等个股表现突出。这主要得益于政策支持、美 联储降息预期和估值修复等因素。不过，中概股的持续性还得看政策的实际效果和企业基本面的改善，咱们要理性看待这波上涨。 各位朋友大家好，这里是帮主郑重的隔夜市场解读时间。接下来咱们来聊聊隔夜市场的那些大事，看看有哪些值得咱们关注的信号。 先说美股，那叫一个涨势如虹啊。三大指数收盘都涨超1%，道指创3月初以来新高，标普和纳指也创下2月下旬以来的新高。大型科技股多数上涨，英特 尔涨超6%，英伟达、奈飞、亚马逊也都涨超2%，不过特斯拉跌超2%，苹果小幅下跌。科技股七巨头整体表现不错，英伟达和亚马逊涨超2%，AMD更是 收涨6.83%，台积电ADR也刷新了收盘历史高位。这说明科技股的热度依然不减，尤其是AMD，最近可是出尽了风头。 说到AMD，那就不得不提它包揽亚马逊CPU热销榜 ...

Group 1 - The Hong Kong IPO market has shown remarkable performance in the first half of the year, with 31 listings and a total financing amount of 884 billion HKD, surpassing the total financing of the previous year, making Hong Kong the global leader in IPO financing [1] - Institutional innovations have activated the financing momentum of the Hong Kong Stock Exchange, with optimized listing rules and improved approval efficiency being key drivers for attracting companies to list [2] - Leading companies in new economy and technology sectors have significantly contributed to Hong Kong's position as the top IPO financing venue globally, with major firms like CATL and Jiangsu Hengrui Medicine leading the way [2][3] Group 2 - The trend of A-share listed companies, especially in new economy and biomedicine sectors, seeking international development through Hong Kong listings is increasing, as the Hong Kong Stock Exchange responds to the demand for high-quality economic development [3] - The liquidity of the Hong Kong market has improved significantly, with a notable reduction in the price gap between H-shares and A-shares, enhancing the attractiveness of IPOs [4] - The continuous release of institutional dividends, the accelerated gathering of new economy industries, and the increasing convenience of cross-border capital flows are expected to strengthen Hong Kong's competitive advantage in attracting global new economy enterprises [4]

供需优化，行业增长韧性十足——2025 下半年教育行业 投资策略 20250624 摘要 2025 年上半年，港美股教育指数绝对回报约为 8.8%，但受教培行业拖 累，相对于恒生国企指数的超额收益为负 10%。港股民办高职教及职业 教育板块表现强劲，收益超过 50%，其中中国东方教育表现突出。 大学毕业生和高考落榜生数量增加，技能培训市场关注度提升。高中阶 段招生数持续增加，但大学扩招相对缓慢，导致高考落榜生数量增加， 职业技能培训需求井喷。青年人群失业率较高，对职业技能培训需求更 强烈。 高中阶段招生人数持续扩张，普通高中入学率提升和职业高中招生吸引 力增加，导致初中毕业生进入劳动力市场的人数减少。普通高中录取人 数通过扩招从过去五年的 50%升至 60%。 高中阶段扩容导致毕业生数量增加，但大学招生未能完全承载，高考落 榜现象显著。近三年大学平均招生增速仅 2.2%，而高中阶段年度增速 超过 5%，导致高中毕业后未升上大学的人数快速增加。 Q&A 2025 年下半年教育行业的投资策略是什么？ 2025 年下半年教育行业的投资策略主要集中在职业技能培训、高等教育和教 培行业特许经营三个方面。首先，青年人群职 ...

点击 最 下方 关注《材料汇》 ， 点击"❤"和" "并分享 添加 小编微信 ，寻 志同道合 的你 正文 材料行业产业链 材料原料/辅料 原油/矿产开采 重化工行业 制造行业 新材料行业投资集中于红框两块 材料成品 制造行业 成品制造/组装行业 半成品制造行业 终端/消费者 新材料定义与分类 M 图 汇 新材料是指新沂发展的或正在研发的 性能超胖的 目有比传统材料面为优豆的性能 假局 环墙影响 le :3 带征 气氛、温度、压力状 ■ 新型功能材料 ■ 新型结构材料 会属材料 से के 无机非金属材料 有机高分子材料 ■复合材料 (使用效能 图 材料科学与工程的内 形态与结构 ■电子信息材料 ■薄膜材料 ■电功能材料 前沿技术新型材料 ■新能源材料 =超微细材料 a 磁力能材料 技术新 结构、性能、功能的新 ■纳米材料 ■纤维材料 ■热功能材料 ■先进复合材料 ■多孔材料 ■力功能材料 ■牛态环境材料 ■无气孔材料 =光功能材料 工艺新 工艺方面的合成与制备方法新 ■生物医用材料 复合材料 = 吉功能材料 重点行业高端材料 图智能材料 多层材料 ■化学功能材料 ■高性能结构材料 日E島材料 ■生物医学功能材 ...

Investment Rating - The report maintains an "Outperform" rating for the agricultural products sector [1][5][4]. Core Views - The report is optimistic about the reversal of the beef cycle and recommends investments in leading companies in the livestock sector, particularly in beef and raw milk, which are expected to experience a positive resonance in 2025 [3][4]. - The pet industry is highlighted as a growth sector benefiting from demographic changes, while the feed sector, particularly Haida Group, is expected to gain from the recovery in aquaculture [3][4]. - The report notes that the pig industry shows insufficient expansion willingness, but the overall market conditions are expected to remain stable through 2025, with a focus on undervalued leading companies [3][4]. - Poultry production is expected to maintain low volatility, with white chicken consumption gradually increasing and yellow chicken likely to benefit from improved domestic demand [3][4]. Summary by Sections Livestock - **Pork**: The average price of live pigs is 14.16 CNY/kg, with a week-on-week increase of 1.22%. The price of 7kg piglets is approximately 446 CNY/head, down 4.98% week-on-week [1][13]. - **Beef**: The domestic beef market price is 59.35 CNY/kg, showing a slight decrease of 0.05% week-on-week but a significant increase of 27.63% year-on-year [1][15]. - **Poultry**: The price of broiler chicks is 1.23 CNY/bird, down 43% week-on-week, while the price of eggs in major production areas is 2.90 CNY/jin, up 9.85% week-on-week but down 35.27% year-on-year [1][14]. Feed and Raw Materials - **Soybean Meal**: The spot price is 3024 CNY/ton, with a week-on-week increase of 1%. The report indicates strong support for supply and demand in the medium to long term [2][3]. - **Corn**: The domestic corn spot price is 2415 CNY/ton, with a week-on-week increase of 0.37% and a year-on-year increase of 0.12% [2][3]. - **Sugar**: The price in Guangxi is 5980 CNY/ton, down 0.17% week-on-week, with attention on import rhythms and crude oil price fluctuations [2][3]. Investment Recommendations - Recommended stocks include: - **Beef**: Guangming Meat Industry - **Pets**: Guibao Pet, Zhongchong Co., and Ruipu Biological - **Feed**: Haida Group - **Pork**: Dekang Agriculture, Muyuan Foods, Huazhong Agriculture, and others - **Poultry**: Lihua Co., Yisheng Co., and Shengnong Development [3][4].

Core Insights - The 2025 Summer Davos Forum will be held in Tianjin from June 24-26, focusing on the theme of "Entrepreneurial Spirit in the New Era" [1] Group 1: AI in Healthcare - AI technology can significantly enhance the quality of medical diagnosis and treatment by integrating years of patient medical history into a visual timeline, allowing doctors to better understand patient conditions [3] - The AI decision support system can provide multiple treatment suggestions for complex cases, aiding doctors in making more accurate clinical decisions [3] - Clinical trial costs have been reduced by 30%-40% due to the integration of AI and data platforms, which can automate many previously manual processes [3] Group 2: Industry Challenges and Opportunities - The healthcare industry is challenging to navigate, with recent market and policy changes prompting the company to adopt a cautious approach to commercialization [4] - The recent activity in the secondary market for innovative drugs reflects a valuation correction, recognizing China's potential as a research-driven market [4] - The Chinese biopharmaceutical ecosystem is expected to grow, with more companies pursuing international collaborations and contributing to global healthcare [4] Group 3: Future Outlook - Future healthcare scenarios envision the integration of historical medical data with wearable devices, providing a comprehensive understanding of individual health and 24/7 personalized health advice through AI [5] - AI is expected to significantly lower new drug development costs, helping more drugs avoid the "orphan drug" dilemma [5] - Insurance coverage is anticipated to expand, with initiatives like the company's "Hui Min Bao" providing coverage for a wide range of patients, including those with pre-existing conditions [5]

文 | 银行螺丝钉 （转载请注明出处） 今天大盘整体上涨，截止到收盘，还在5星，距离4.9星很接近。 大中小盘股都上涨，中小盘上涨更多一些。 价值风格微涨，成长风格上涨较多。 300价值、优选300回到正常估值，距离低估也不远。 港股也整体上涨。 港股还是比较强势。从4月初下跌之后，港股9周里有8周上涨。 上周港股出现小幅回调，但本周继续上涨。 港股科技股领涨，港股科技也回到正常估值。 周一原油价格大幅下跌，能源价格下降，有助于降低通胀水平，推动美联储的降息节奏。 今天全球股票市场也都出现了上涨。 1. [大吉大利，今天吃基] 第370期的螺丝钉定投实盘来啦。 PS：组合底层投资基金、各自比例等都是透明的，可以在公众号底部对话框回复「 发车方案 」查看。 2. 两种组合跟车方式，可以自由选择。 时间：2025年6月24日 方案：定投买入 品种： 指数增强投顾组合：10881元 主动优选投顾组合： 12219元 点击下图，即可立即跟投买入： 点击下图，即可立即跟投买入： 定投 金额采用的是 「定期不定额」的策略，估值越低投入越多。 实际使用参考金额的时候，可以根据自己的资金，按照一定比例来定投。 例如资金较少的 ...

Core Viewpoint - The release of mid-year performance forecasts significantly impacts the re-evaluation of listed companies' valuations, necessitating thorough analysis by investors [1] Group 1: Importance of Performance Forecasts - Mid-year performance forecasts are crucial for the capital market as they reflect market expectations regarding a company's future profitability and development prospects [1] - Positive performance forecasts can lead to an upward adjustment in valuations, attracting more capital and driving stock prices up, while negative forecasts may raise concerns about future development, leading to valuation downgrades and stock price pressure [1] Group 2: Comparative Analysis - Comparing a company's performance forecast with its competitors is essential for understanding its industry position and future prospects [2] - A significant increase in a company's performance compared to competitors, along with advantages in market share and technological innovation, may indicate a favorable competitive position and greater investment potential [2] - Conversely, if a company's performance lags behind competitors, it is important to investigate the reasons and assess potential challenges and investment risks [2] Group 3: Historical Performance Comparison - Comparing current performance forecasts with a company's historical performance helps assess the sustainability of growth and stability [2] - Consistent and stable growth in past performance, along with a positive current forecast, indicates strong operational capability and resilience, warranting long-term attention [2] - Significant fluctuations in past performance, especially with a current forecast showing a sharp decline, should prompt caution among investors to avoid potential investment traps [2] Group 4: Analytical Approach - A multi-faceted analysis of mid-year performance forecasts aids investors in accurately evaluating a company's value and provides a scientific basis for investment decisions [3] - Maintaining keen insight and a rigorous analytical approach is essential for identifying genuine investment opportunities amidst complex market information [3]

Core Viewpoint - The Chinese innovative drug sector is experiencing a resurgence, driven by active business development (BD) transactions and favorable policies, leading to improved revenue expectations for innovative drug companies starting from mid-2024 [1][4][6]. Group 1: Market Performance - The Hong Kong innovative drug ETFs saw increases of 2.25% and 1.15% respectively on June 24, with notable stock price rises for companies like Rongchang Biopharma (6.38% increase in A-shares) and Green Leaf Pharmaceutical (over 9.5% increase in H-shares) [1]. - The A-share innovative drug sector has risen nearly 25% from its low on April 8 to June 23, with a total inflow of 945 billion and financing purchases of 1,148 billion [4]. Group 2: Business Development Trends - There has been a significant increase in "outbound" BD transactions for Chinese innovative drugs, with major deals such as the 6.7 billion USD agreement between Heptares and Otsuka Pharmaceutical [2]. - The trend of international pharmaceutical companies acquiring innovative drug projects before commercialization is becoming more common, driven by the need to replenish their pipelines due to patent expirations [2][3]. Group 3: Financial Performance - Companies like Saint Noble Bio are forecasting substantial profit increases, with expected net profits for the first half of 2025 projected to grow by 253.54% to 332.1% year-on-year [4]. - A total of 17 commercialized innovative drug companies are expected to achieve 913 billion in product sales revenue in 2024, reflecting a 35% year-on-year growth [5]. Group 4: Policy Support - Recent policies have been implemented to support innovative drug development, including expedited clinical trial approvals and a multi-layered insurance system that combines basic medical insurance with commercial insurance [6]. - The introduction of commercial health insurance for innovative drugs is expected to enhance the market environment, transitioning from reliance on basic medical insurance to a dual support system [6]. Group 5: Long-term Outlook - The innovative drug sector is anticipated to continue its upward trajectory due to ongoing policy support, technological advancements, and international expansion, with a potential for sustained valuation reassessment [7]. - Increased investment in innovative drug companies is expected, although caution is advised regarding potential overvaluation in some cases [7].

6月24日收盘，沪指重回3400点上方， 创业板指领涨。沪深两市全天成交额1.41万亿，较上个交易日放 量2920亿。截至收盘，A500ETF银河( 563660)上涨1.02%，最新价报0.99元。 成分股方面， 国轩高科 (002074)上涨10.02%， 光迅科技(002281)上涨10.00%， 容百科技(688005)上涨8.26%。 中国银河证券表 示，A股当前估值处于历史中等水平，且相较海外成熟市场偏低，风险溢价和股息率具备较高投资性价 比。在政策推动中长期资金入市、权益类公募基金扩容及政策工具护航下，A股资金面有望延续稳中向 好态势。 华金证券表示，国内政策持续积极，如央行在 陆家嘴论坛推出多项金融开放举措，以及财政 补贴推动内需修复。流动性方面，美元指数低位震荡、人民币升值预期增强，有利于外资流入。行业配 置方面，建议聚焦估值性价比，均衡配置科技成长与低估值蓝筹。 市场风格快速轮动，博弈属性加 剧， 中证A500指数等均衡宽基或是把握估值中枢提升的较好方式。银河基金身为国内资产管理能力突 出的老牌基金公司，深耕资管领域23载 。作为银河基金旗下紧密跟踪中证 A500 指数的 ETF 产品， ...